ARS Pharmaceuticals, Inc. SPRY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$60.62M-46.7% | -$41.32M+19.2% | -$51.15M-14.0% | -$44.88M-32.2% | -$33.94M-168% | ||
| $397K-4.8% | $417K+6.6% | $391K+40.1% | $279K-0.4% | $280K+866% | ||
| $7.42M+29.4% | $5.74M+0.8% | $5.69M+5.9% | $5.37M+1.4% | $5.3M+24.3% | ||
| $839K— | —— | $14.01M+5.7% | $13.25M+1,074% | $1.13M-84.8% | ||
| $294K-97.0% | $9.72M— | $0-100% | $4.78M-43.4% | $8.45M+46.6% | ||
| $10.32M— | —— | $10.96M-14.4% | $12.81M+207% | $4.17M-45.6% | ||
| $524K+285% | -$284K+73.4% | -$1.07M+73.9% | -$4.1M-185% | $4.8M-33.9% | ||
| -$245K-62.3% | -$151K— | —— | —— | $4K— | ||
| -$61K-10.9% | -$55K0.0% | -$55K-83.3% | -$30K+85.7% | -$210K-110% | ||
| -$44.95M-3.4% | -$43.49M+7.6% | -$47.05M-18.8% | -$39.59M+2.8% | -$40.74M-197% | ||
| $0— | $0-100% | $197K+286% | $51K-44.0% | $91K-69.9% | ||
| $14.71M-69.9% | $48.89M-61.6% | $127.42M+306% | $31.38M-8.6% | $34.35M-79.0% | ||
| $42.5M-43.3% | $75M-15.3% | $88.5M+10.6% | $80M+26.0% | $63.5M-5.2% | ||
| $27.79M+15.2% | $24.11M— | —— | $48.57M+67.1% | $29.06M+129% | ||
| $62K-96.5% | $1.78M+272% | $479K-82.2% | $2.7M+272% | $725K-52.7% | ||
| $159K-85.9% | $1.13M-98.9% | $100.05M+3,609% | $2.7M+272% | $725K-99.0% | ||
| -$17M+6.8% | -$18.24M-328% | $8.02M-31.3% | $11.68M+207% | -$10.95M— | ||
| $2.29M— | —— | —— | —— | $0— | ||
| $990K-1.3% | $1M-8.2% | $1.09M-25.6% | $1.47M-25.2% | $1.96M+27.0% | ||
| $524K+285% | -$284K+73.4% | -$1.07M+73.9% | -$4.1M-185% | $4.8M-33.9% | ||
| -$245K-62.3% | -$151K— | —— | —— | $4K— | ||
| $14.71M-69.9% | $48.89M-61.6% | $127.42M+306% | $31.38M-8.6% | $34.35M-79.0% | ||
| $42.5M-43.3% | $75M-15.3% | $88.5M+10.6% | $80M+26.0% | $63.5M-5.2% | ||
| $62K-96.5% | $1.78M+272% | $479K-82.2% | $2.7M+272% | $725K-52.7% | ||
| $97K— | —— | —— | —— | $0— | ||
| $2.53M— | —— | —— | —— | $0— | ||
| -$61K-10.9% | -$55K0.0% | -$55K-83.3% | -$30K+85.7% | -$210K-110% | ||
| -$44.95M-3.4% | -$43.49M+8.0% | -$47.24M-19.2% | -$39.64M+2.9% | -$40.83M-198% | ||
| -$44.95M-3.4% | -$43.49M+8.0% | -$47.24M-19.2% | -$39.64M+2.9% | -$40.83M-198% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ARS Pharmaceuticals, Inc. generate?
- ARS Pharmaceuticals, Inc. (SPRY) generated -$175.1M in operating cash flow over the trailing twelve months.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- After $248.0K of capital expenditures, ARS Pharmaceuticals, Inc.'s free cash flow was -$175.3M over the trailing twelve months, down 732.7% year over year.
- Where does ARS Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
